文献速递乳腺癌

2016至2020年全球癌症研究资助:公共与慈善投资的内容分析

Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments.
PubMed 文献 · Lancet Oncol · 2023-01-01

投资逐年下降,2019至2020年降幅最大;临床前研究占73.5%,1-4期临床试验占7.4%,公共卫生研究占9.4%,跨学科研究占5.0%。作者认为资助需与全球癌症负担对齐,并优先投资外科与放疗研究。

核心结论

  • 癌症研究资助必须与全球癌症负担对齐,对低收入和中等收入国家(占癌症负担80%)的癌症研究应更公平资助,以支持与这些环境相关的研究并在这些国家建设研究能力。
  • 作者认为鉴于外科和放疗在许多实体瘤治疗中的首要地位,迫切需要优先投资外科和放疗研究。

研究设计与样本

  • 本研究为内容分析,检索UberResearch Dimensions数据库与英国癌症研究数据,纳入2016年1月1日至2020年12月31日公共与慈善资助者的人类癌症研究资助。
  • 纳入的资助类型为项目与 programme 资助、 fellowship、 pump priming 和试点项目,排除聚焦癌症照护运营实施的资助。
  • 资助按癌症类型、跨领域研究主题和研究阶段分类,并将资助金额与全球特定癌症负担(以伤残调整生命年、伤残损失健康生命年和死亡率衡量,数据来自全球疾病负担研究)比较。

主要发现

  • 总资助的1.4%(3亿美元)用于外科研究,2.8%(7亿美元)用于放疗研究,0.5%(1亿美元)用于全球健康研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer is a leading cause of disease burden globally, with more than 19·3 million cases and 10 million deaths recorded in 2020. Research is crucial to understanding the determinants of cancer and the effects of interventions, and to improving outcomes. We aimed to analyse global patterns of public and philanthropic investment in cancer research. METHODS: In this content analysis, we searched the UberResearch Dimensions database and Cancer Research UK data for human cancer research funding awards from public and philanthropic funders between Jan 1, 2016, and Dec 31, 2020. Included award types were project and programme grants, fellowships, pump priming, and pilot projects. Awards focused on operational delivery of cancer care were excluded. Awards were categorised by cancer type, cross-cutting research theme, and research phase. Funding amount was compared with global burden of specific cancers, measured by disability-adjusted life-years, years lived with disability, and mortality using data from the Global Burden of Disease study. FINDINGS: We identified 66 388 awards with total investment of about US$24·5 billion in 2016-20. Investment decreased year-on-year, with the largest drop observed between 2019 and 2020. Pre-clinical research received 73·5% of the funding across the 5 years ($18 billion), phase 1-4 clinical trials received 7·4% ($1·8 billion), public health research received 9·4% ($2·3 billion), and cross-disciplinary research received 5·0% ($1·2 billion). General cancer research received the largest investment ($7·1 billion, 29·2% of the total funding). The most highly funded cancer types were breast cancer ($2·7 billion [11·2%]), haematological cancer ($2·3 billion [9·4%]), and brain cancer ($1·3 billion [5·5%]). Analysis by cross-cutting theme revealed that 41·2% of investment ($9·6 billion) went to cancer biology research, 19·6% ($4·6 billion) to drug treatment research, and 12·1% ($2·8 billion) to immuno-oncology. 1·4% of the total funding ($0·3 billion) was spent on surgery research, 2·8% ($0·7 billion) was spent on radiotherapy research, and 0·5% ($0·1 billion) was spent on global health studies. INTERPRETATION: Cancer research funding must be aligned with the global burden of cancer with more equitable funding for cancer research in low-income and middle-income countries (which account for 80% of cancer burden), both to support research relevant to these settings, and build research capacity within these countries. There is an urgent need to prioritise investment in surgery and radiotherapy research given their primacy in the treatment of many solid tumours. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. McIntosh SA, Alam F, Adams L, et al. Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments. Lancet Oncol. 2023. PMID: 37269844. doi:10.1016/S1470-2045(23)00182-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。